CYCN
NASDAQCyclerion Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$4.08-0.13 (-3.20%)
02:00 PM06:15 PM
News · 26 weeks25+43%
2026-03-012026-08-23
Mix1890d
- SEC Filings13(72%)
- Insider3(17%)
- Other2(11%)
Latest news
25 items- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 8-K filed by Cyclerion Therapeutics Inc.8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- INSIDERChief Financial Officer Chicko Rhonda M. exercised 25,000 shares at a strike of $2.35, increasing direct ownership by 138,889% to 25,018 units (SEC Form 4)4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
- INSIDEROfficer Graul Regina Margaret exercised 55,849 shares at a strike of $3.30 and covered exercise/tax liability with 48,629 shares, increasing direct ownership by 7% to 107,523 units (SEC Form 4)4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Cyclerion Therapeutics Inc.SCHEDULE 13G - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form 10-Q filed by Cyclerion Therapeutics Inc.10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECSEC Form EFFECT filed by Cyclerion Therapeutics Inc.EFFECT - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 424B3 filed by Cyclerion Therapeutics Inc.424B3 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECAmendment: SEC Form S-4/A filed by Cyclerion Therapeutics Inc.S-4/A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Cyclerion Therapeutics Inc.SCHEDULE 13D/A - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- INSIDERDirector Hecht Peter M converted options into 351,037 shares, increasing direct ownership by 63% to 910,240 units (SEC Form 4)4 - Cyclerion Therapeutics, Inc. (0001755237) (Issuer)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECAmendment: SEC Form S-4/A filed by Cyclerion Therapeutics Inc.S-4/A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECAmendment: SEC Form S-4/A filed by Cyclerion Therapeutics Inc.S-4/A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 10-Q filed by Cyclerion Therapeutics Inc.10-Q - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form SCHEDULE 13G filed by Cyclerion Therapeutics Inc.SCHEDULE 13G - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECAmendment: SEC Form 10-K/A filed by Cyclerion Therapeutics Inc.10-K/A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form S-4 filed by Cyclerion Therapeutics Inc.S-4 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- SECSEC Form 425 filed by Cyclerion Therapeutics Inc.425 - Cyclerion Therapeutics, Inc. (0001755237) (Subject)
- SECCyclerion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
- PRCyclerion Therapeutics and Korsana Biosciences Announce Merger AgreementCombined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases Korsana's lead program KRSA-028 is a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease Concurrent private financing of approximately $380 million expected to fund Korsana's operations into 2029, including multiple clinical trial data readouts expected in 2027 Conference call scheduled for April 1, 2026, at 8:00 am ET Cyclerion Therapeutics, Inc. ("Cyclerion") (NASDAQ:CYCN) and Korsana Biosciences, Inc. ("Korsana"), a privately-held biotechnology company discovering and developin
CYCN FAQ
6 questionsWhat does Cyclerion Therapeutics Inc. do?
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for...Where does CYCN stock trade?
Cyclerion Therapeutics Inc. (CYCN) is listed on NASDAQ.What sector and industry is CYCN in?
Cyclerion Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CYCN?
Cyclerion Therapeutics Inc. has had 2 recent analyst actions on file. The most recent action was from Truist Securities: Buy with a $1400.00 price target on 2021-10-20. Recent price targets range from $700.00 to $1400.00.What companies are similar to CYCN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CYCN side-by-side with any of them on Quantisnow.How can I track CYCN on Quantisnow?
Quantisnow aggregates Cyclerion Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CYCN to receive live email and push alerts on every new disclosure.